Evidence map›Paper›PMID 35708340›Full record

ArticleMicrobiology spectrum2022

Multiplex Target-Redundant RT-LAMP for Robust Detection of SARS-CoV-2 Using Fluorescent Universal Displacement Probes.

Enos C Kline, Nuttada Panpradist, Ian T Hull, Qin Wang, Amy K Oreskovic, Peter D Han, Lea M Starita, Barry R Lutz

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Passively sensing SARS-CoV-2 RNA in public transit buses.The Science of the total environment · 2022
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Enos C KlineDepartment of Bioengineering, University of Washingtongrid.34477.33, Seattle, Washington, USA.ORCID 0000-0002-3879-5289
Nuttada PanpradistDepartment of Bioengineering, University of Washingtongrid.34477.33, Seattle, Washington, USA.ORCID 0000-0002-2733-4110
Ian T HullDepartment of Bioengineering, University of Washingtongrid.34477.33, Seattle, Washington, USA.ORCID 0000-0002-4875-5651
Qin WangDepartment of Bioengineering, University of Washingtongrid.34477.33, Seattle, Washington, USA.
Amy K OreskovicDepartment of Bioengineering, University of Washingtongrid.34477.33, Seattle, Washington, USA.ORCID 0000-0003-4911-4431
Peter D HanDepartment of Genome Sciences, University of Washingtongrid.34477.33, Seattle, Washington, USA.
Lea M StaritaDepartment of Genome Sciences, University of Washingtongrid.34477.33, Seattle, Washington, USA.ORCID 0000-0003-2870-5099
Barry R LutzDepartment of Bioengineering, University of Washingtongrid.34477.33, Seattle, Washington, USA.ORCID 0000-0003-4298-4901
University of Washington · US

Funding

TRAINING IN MOLECULAR BIOPHYSICST32GM008268 · NIGMS · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M, ZHENG, NING · 1988 to 2023
$8.6M
V-OLA: point-of-care HIV viral load monitoring and drug resistance testingR01AI145486 · NIAID · UNIVERSITY OF WASHINGTON · PI Barry Ryan Lutz · 2019 to 2026
$5.6M
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoringR33AI140460 · NIAID · UNIVERSITY OF WASHINGTON · PI LUTZ, BARRY RYAN · 2021 to 2022
$1.5M
HIV-specific target capture and quantitative isothermal amplification for acute HIV diagnosis and treatment monitoringR61AI140460 · NIAID · UNIVERSITY OF WASHINGTON · PI LUTZ, BARRY RYAN · 2018 to 2020
$1.4M
NIAID NIH HHS R01 AI145486NIAID NIH HHS R33 AI140460NIAID NIH HHS R61 AI140460NIGMS NIH HHS T32 GM008268
6 · The paper itself

Abstract

The increasing prevalence of variant lineages during the COVID-19 pandemic has the potential to disrupt molecular diagnostics due to mismatches between primers and variant templates. Point-of-care molecular diagnostics, which often lack the complete functionality of their high-throughput laboratory counterparts, are particularly susceptible to this type of disruption, which can result in false-negative results. To address this challenge, we have developed a robust Loop Mediated Isothermal Amplification assay with single tube multiplexed multitarget redundancy and an internal amplification control. A convenient and cost-effective target-specific fluorescence detection system allows amplifications to be grouped by signal using adaptable probes for pooled reporting of SARS-CoV-2 target amplifications or differentiation of the Internal Amplification Control. Over the course of the pandemic, primer coverage of viral lineages by the three redundant sub-assays has varied from assay to assay as they have diverged from the Wuhan-Hu-1 isolate sequence, but aggregate coverage has remained high for all variant sequences analyzed, with a minimum of 97.4% (Variant of Interest: Eta). In three instances (Delta, Gamma, Eta), a high-frequency mismatch with one of the three sub-assays was observed, but overall coverage remained high due to multitarget redundancy. When challenged with extracted human samples the multiplex assay showed 87% or better sensitivity (of 30 positive samples), with 100% sensitivity for samples containing greater than 30 copies of viral RNA per reaction (of 21 positive samples), and 100% specificity (of 60 negative samples). These results are further evidence that conventional laboratory methodologies can be leveraged at the point of care for robust performance and diagnostic stability over time.

Indexed as

COVID-19SARS-CoV-2Clinical Laboratory TechniquesCOVID-19 TestingFluorescent DyesHumansMolecular Diagnostic TechniquesNucleic Acid Amplification TechniquesPandemicsSensitivity and SpecificityFluorescent Dyescoronavirusdiagnosticsmolecular methods

Identifiers

PMID35708340
PMCPMC9430505
OpenAlexW4283012913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.